The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
The Acid-Mediated Denaturation Pathway of Transthyretin Yields a Conformational Intermediate That Can Self-Assemble into Amyloid
Abstract
Transthyretin (TTR) amyloid fibril formation is observed during partial acid denaturation and while refolding acid-denatured TTR, implying that amyloid fibril formation results from the self-assembly of a conformational intermediate. The acid denaturation pathway of TTR has been studied in detail herein employing a variety of biophysical methods to characterize the intermediate(s) capable of amyloid fibril formation. At physiological concentrations, tetrameric TTR remains associated from pH 7 to pH 5 and is incapable of amyloid fibril formation. Tetrameric TTR dissociates to a monomer in a process that is dependent on both pH and protein concentration below pH 5. The extent of amyloid fibril formation correlates with the concentration of the TTR monomer having an altered, but defined, tertiary structure over the pH range of 5.0-3.9. The inherent Trp fluorescence-monitored denaturation curve of TTR exhibits a plateau over the pH range where amyloid fibril formation is observed (albeit at a higher concentration), implying that a steady-state concentration of the amyloidogenic intermediate with an altered tertiary structure is being detected. Interestingly, 1-anilino-8-naphthalenesulfonate fluorescence is at a minimum at the pH associated with maximal amyloid fibril formation (pH 4.4), implying that the amyloidogenic intermediate does not have a high extent of hydrophobic surface area exposed, consistent with a defined tertiary structure. Transthyretin has two Trp residues in its primary structure, Trp-41 and Trp-79, which are conveniently located far apart in the tertiary structure of TTR. Replacement of each Trp with Phe affords two single Trp containing variants which were used to probe local pH-dependent tertiary structural changes proximal to these chromophores. The pH-dependent fluorescence behavior of the Trp-79-Phe mutant strongly suggests that Trp-41 is located near the site of the tertiary structural rearrangement that occurs in the formation of the monomeric amyloidogenic intermediate, likely involving the C-strand-loop-D-strand region. Upon further acidification of TTR (below pH 4.4), the structurally defined monomeric amyloidogenic intermediate begins to adopt alternative conformations that are not amyloidogenic, ultimately forming an A-state conformation below pH 3 which is also not amyloidogenic. In summary, analytical equilibrium ultracentrifugation, SDS-PAGE, far- and near-UV CD, fluorescence, and light scattering studies suggest that the amyloidogenic intermediate is a monomeric predominantly beta-sheet structure having a well-defined tertiary structure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
X-RAY DIFFRACTION STUDIES ON AMYLOID FILAMENTS
EANES, E. D., & GLENNER, G. G. (1968) · Journal of Histochemistry & Cytochemistry · doi:10.1177/16.11.673 · Cited by 823
Alternative conformations of amyloidogenic proteins govern their behavior
Kelly, J. W. (1996) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(96)80089-3 · Cited by 593
Self-citationβ-PLEATED SHEET FIBRILS A COMPARISON OF NATIVE AMYLOID WITH SYNTHETIC PROTEIN FIBRILS
GLENNER, G. G., EANES, E. D., BLADEN, H. A., LINKE, R. P., & TERMINE, J. D. (1974) · Journal of Histochemistry & Cytochemistry · doi:10.1177/22.12.1141 · Cited by 290
Aggregation State and Neurotoxic Properties of Alzheimer Beta-Amyloid Peptide
Howlett, D. R., Jennings, K. H., Lee, D. C., Clark, M. S. G., Brown, F., Wetzel, R., Wood, S. J., Camilleri, P., & Roberts, G. W. (1995) · Neurodegeneration · doi:10.1006/neur.1995.0003 · Cited by 204
Comparison of Lethal and Nonlethal Transthyretin Variants and Their Relationship to Amyloid Disease
McCutchen, S. L., Lai, Z., Miroy, G. J., Kelly, J. W., & Colon, W. (1995) · Biochemistry · doi:10.1021/bi00041a032 · Cited by 198
Self-citationThe chemistry of scrapie infection: implications of the ‘ice 9’ metaphor
Lansbury, P. T., & Caughey, B. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90074-8 · Cited by 169
Circular Dichroism of Peptides
WOODY, R. W. (1985) · Conformation in Biology and Drug Design · doi:10.1016/b978-0-12-304207-1.50008-4 · Cited by 166
[12]Refolding and association of oligomeric proteins
Jaenicke, R., & Rudolph, R. (1986) · Methods in Enzymology · doi:10.1016/0076-6879(86)31043-7 · Cited by 165
Fraser, P. E., McLachlan, D. R. C., Surewicz, W. K., Mizzen, C. A., Snow, A. D., Nguyen, J. T., & Kirschner, D. A. (1994) · Journal of Molecular Biology · doi:10.1006/jmbi.1994.1704 · Cited by 156
Structure of Met30 variant of transthyretin and its amyloidogenic implications.
Terry, C. J., Damas, A. M., Oliveira, P., Saraiva, M. J., Alves, I. L., Costa, P., Matias, P. M., Sakaki, Y., & Blake, C. C. F. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05707.x · Cited by 109
Cited by
Protein aggregation: folding aggregates, inclusion bodies and amyloid
Fink, A. L. (1998) · Folding and Design · doi:10.1016/s1359-0278(98)00002-9 · Cited by 1,157
Experimental Constraints on Quaternary Structure in Alzheimer's β-Amyloid Fibrils
Petkova, A. T., Yau, W.-M., & Tycko, R. (2006) · Biochemistry · doi:10.1021/bi051952q · Cited by 1,044
Designing conditions for in vitro formation of amyloid protofilaments and fibrils
Chiti, F., Webster, P., Taddei, N., Clark, A., Stefani, M., Ramponi, G., & Dobson, C. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3590 · Cited by 1,039
Conformational constraints for amyloid fibrillation: the importance of being unfolded
Uversky, V. N., & Fink, A. L. (2004) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.12.008 · Cited by 1,015
The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways
Kelly, J. W. (1998) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(98)80016-x · Cited by 1,001
Self-citationAmyloid formation by globular proteins under native conditions
Chiti, F., & Dobson, C. M. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.131 · Cited by 812
Identifying the amylome, proteins capable of forming amyloid-like fibrils
Goldschmidt, L., Teng, P. K., Riek, R., & Eisenberg, D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915166107 · Cited by 809
Amyloid fibril formation by an SH3 domain
Guijarro, J. I., Sunde, M., Jones, J. A., Campbell, I. D., & Dobson, C. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4224 · Cited by 669
Hamley, I. W. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700861 · Cited by 618
Alternative conformations of amyloidogenic proteins govern their behavior
Kelly, J. W. (1996) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(96)80089-3 · Cited by 593
Self-citationTabulation of human transthyretin (TTR) variants, 2003
Connors, L. H., Lim, A., Prokaeva, T., Roskens, V. A., & Costello, C. E. (2003) · Amyloid · doi:10.3109/13506120308998998 · Cited by 505
The Biological and Chemical Basis for Tissue-Selective Amyloid Disease
Sekijima, Y., Wiseman, R. L., Matteson, J., Hammarström, P., Miller, S. R., Sawkar, A. R., Balch, W. E., & Kelly, J. W. (2005) · Cell · doi:10.1016/j.cell.2005.01.018 · Cited by 488
Self-citationFormation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy
Bouchard, M., Zurdo, J., Nettleton, E. J., Dobson, C. M., & Robinson, C. V. (2000) · Protein Science · doi:10.1110/ps.9.10.1960 · Cited by 482
Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease
Adams, D., Koike, H., Slama, M., & Coelho, T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0210-4 · Cited by 448
Targeting protein aggregation for the treatment of degenerative diseases
Eisele, Y. S., Monteiro, C., Fearns, C., Encalada, S. E., Wiseman, R. L., Powers, E. T., & Kelly, J. W. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4593 · Cited by 419
Self-citationSanchez-Ruiz, J. M. (2010) · Biophysical Chemistry · doi:10.1016/j.bpc.2010.02.004 · Cited by 367
Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity
Hammarström, P., Jiang, X., Hurshman, A. R., Powers, E. T., & Kelly, J. W. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202495199 · Cited by 359
Self-citationConformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in Vitro
Kayed, R., Bernhagen, J., Greenfield, N., Sweimeh, K., Brunner, H., Voelter, W., & Kapurniotu, A. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2646 · Cited by 351
Lindgren, M., Sörgjerd, K., & Hammarström, P. (2005) · Biophysical Journal · doi:10.1529/biophysj.104.049700 · Cited by 349
Inhibiting transthyretin amyloid fibril formation via protein stabilization
Miroy, G. J., Lai, Z., Lashuel, H. A., Peterson, S. A., Strang, C., & Kelly, J. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15051 · Cited by 344
Self-citationKinetic Studies of Amyloid β-Protein Fibril Assembly
Fezoui, Y., & Teplow, D. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204168200 · Cited by 342
Sekijima, Y. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308724 · Cited by 332
Johnson, S. M., Connelly, S., Fearns, C., Powers, E. T., & Kelly, J. W. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.060 · Cited by 328
Self-citationUversky, V. N. (2003) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3096-6 · Cited by 314
Modulation of Protein–Protein Interactions with Small Organic Molecules
Berg, T. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200558 · Cited by 292
Mutant p53 Aggregates into Prion-like Amyloid Oligomers and Fibrils
Ano Bom, A. P. D., Rangel, L. P., Costa, D. C. F., de Oliveira, G. A. P., Sanches, D., Braga, C. A., Gava, L. M., Ramos, C. H. I., Cepeda, A. O. T., Stumbo, A. C., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.340638 · Cited by 280
Deadly Conformations—Protein Misfolding in Prion Disease
Horwich, A. L., & Weissman, J. S. (1997) · Cell · doi:10.1016/s0092-8674(00)80232-9 · Cited by 278
Chiti, F., Calamai, M., Taddei, N., Stefani, M., Ramponi, G., & Dobson, C. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212527999 · Cited by 273
Inhibition of Amyloid Formation
Härd, T., & Lendel, C. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.062 · Cited by 269
Manipulating the Amyloid-β Aggregation Pathway with Chemical Chaperones
Yang, D.-S., Yip, C. M., Huang, T. H. J., Chakrabartty, A., & Fraser, P. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.46.32970 · Cited by 268
Sekijima, Y., Dendle, M. A., & Kelly, J. W. (2006) · Amyloid · doi:10.1080/13506120600960882 · Cited by 268
Self-citationTransthyretin: a review from a structural perspective
Hamilton, J. A., & Benson, M. D. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000791 · Cited by 264
Therapeutic strategies for human amyloid diseases
Sacchettini, J. C., & Kelly, J. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd769 · Cited by 261
Self-citationA molecular mechanism for transthyretin amyloidogenesis
Yee, A. W., Aldeghi, M., Blakeley, M. P., Ostermann, A., Mas, P. J., Moulin, M., de Sanctis, D., Bowler, M. W., Mueller-Dieckmann, C., Mitchell, E. P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08609-z · Cited by 139
Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis
Butler, J. S., Chan, A., Costelha, S., Fishman, S., Willoughby, J. L. S., Borland, T. D., Milstein, S., Foster, D. J., Gonçalves, P., Chen, Q., et al. (2016) · Amyloid · doi:10.3109/13506129.2016.1160882 · Cited by 113
Gonçalves, N. P., Teixeira-Coelho, M., & Saraiva, M. J. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.04.030 · Cited by 27
Metadata
- Authors
- Lai, Z., Colón, W., & Kelly, J. W.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1996-01-01
- Volume
- 35
- Issue
- 20
- Pages
- 6470-6482
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W1971840315
- Cited by
- 574
- References
- 16
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.